Breakthrough cancer treatment Avastin receives first approval in the US
Roche today announced that Genentech has received approval from the US Food and Drug Administration (FDA) for Avastin (bevacizumab, rhuMAb-VEGF), an innovative new cancer drug, to be used with intravenous 5-Fluorouracil-based chemotherapy as treatment for patients with previously untreated metastatic cancer of the colon or rectum (first-line treatment). Genentech will market Avastin in the US and...Roche files marketing application for Avastin with European health authorities
Roche today announced the submission of a Marketing Authorisation application to the European Union for Avastin (bevacizumab, rhuMAb-VEGF) as a treatment for first-line metastatic colorectal cancer in combination with chemotherapy. The application is based on data from a pivotal clinical study of over 900 patients on Avastin who experienced improved survival benefit compared to chemotherapy trea...A milestone in colorectal cancer unveiled Avastin(TM) confers unprecedented survival advantage
Copenhagen, Denmark, 21 September 2003 Treatment with Avastin (bevacizumab, rhuMAb-VEGF) a new agent designed specifically to restrict the blood supply to tumours can significantly improve survival in advanced colorectal cancer compared to established chemotherapy alone, according to data presented today at the European Cancer Conference (ECCO). This represents the first, long-hoped for clinic...